New clinical trial design promises to accelerate cancer drug approvals

June 14, 2012 By Erika Matich, University of Colorado Denver
New clinical trial design promises to accelerate cancer drug approvals

Patients with early-stage breast cancer usually have to wait years to receive new cancer drugs but new guidance from the Food and Drug Administration (FDA)  promises to reduce substantially the time and cost of getting new treatments to patients.  The approach is based on a trial design being tested in the I-SPY 2 TRIAL, an innovative Phase II breast cancer trial.
University of Colorado Cancer Center is a designated study site for I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2). The trial evaluates which medical treatments are most effective for different types of breast tumors.

“New drugs are usually tested first in patients with advanced stage disease and then approved for use in early stage cancer but only after additional clinical trials. It can take hundreds of thousands of dollars and several years to study one drug,” said Anthony Elias, MD, program director and associate director for clinical research at CU Cancer Center.  “I-SPY 2 shows us that we can find the treatments that work and get them to patients that need them efficiently and safely."
The new FDA recommendations, discussed in the current issue of The New England Journal of Medicine, would speed up approval of drugs tested prior to surgical removal of tumors in certain types of high-risk patients with localized, early stage disease. The centers on neoadjuvant therapy for breast cancer -- the administration of therapeutic agents prior to surgery. The FDA said it may now grant approval to medications that have shown clinical benefit, based on data from patients receiving this type of neoadjuvant treatment whose invasive cancers have disappeared by the time of surgery, termed “pathologic complete response.’’
“Better options for patients with high-risk breast cancer are urgently needed," said Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research at FDA. “The FDA guidance explains how a promising drug identified in trials such as I-SPY 2 could be evaluated for FDA approval, so patients could have rapid access if the drug proved better than current treatments."
The I-SPY 2 Trial, led by Laura Esserman, MD, MBA, at the University of California at San Francisco (UCSF) and Donald Berry, MD, at MD Anderson Cancer Center in Houston, uses specific genetic signatures – biomarkers – in the tumors of patients to select those most likely to benefit from testing using the new approaches.  The biomarkers are also incorporated into a unique “adaptive” trial design that allows researchers to measure the relative benefit of treating patients with different tumor profiles with a specific drug and guide treatment assignments for subsequent trial participants.
I-SPY 2 can test new treatments with significantly fewer participants and in half the traditional time, which will dramatically lower costs under the new guidance.
The use of the I-SPY 2 design as a basis for accelerated drug approvals was first discussed in an article in the December issue of the Journal of the American Medical Association co-authored by Esserman and Woodcock.
“We are truly excited to see that the FDA is supportive of trials like I-SPY 2," said Esserman, the co-principal investigator of I-SPY 2. “This really moves us much closer to getting the right drugs to the right now, and at a time when they can be cured."
The trial, which was launched two years ago, is screening multiple at 19 major cancer research centers across the country, including CU Cancer Center.  Scientists from the National Cancer Institute, FDA, pharmaceutical and biotechnology companies, as well as breast cancer patient advocates also contributed to the design of the trial, which is managed by FNIH and Quantum Leap Healthcare Collaborative with support from Quintiles, a global biopharmaceuticals services provider.  Funding for I-SPY 2 is provided by non-profit foundations including The Safeway Foundation, several pharmaceutical companies, and other private sector and philanthropic donors.

is accepting public comment on the new recommendations through July.

Explore further: Cancer drugs: better, cheaper

Related Stories

Cancer drugs: better, cheaper

June 4, 2012
Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access ...

Tracking breast cancer over decades to save lives

September 30, 2011
A new way to study and treat breast cancer being launched at the University of California, San Francisco (UCSF) in October will screen women for the disease and provide them with individual assessments of their risk of developing ...

Combination therapy for triple-negative breast cancer disappointing

June 13, 2012
(Medical Xpress) -- A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not ...

Early-stage lung cancer treatments evaluated in patients with breathing problems

April 10, 2012
(Medical Xpress) -- The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is seeking patients for a clinical study to determine the best treatment for patients with ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.